{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:02:07Z","timestamp":1791597727751,"version":"4.3.4"},"reference-count":125,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec id=\"ab-jrv260016-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Hodgkin lymphoma (HL) is a lymphoid malignancy derived from B cells. Globally, there were 82\u202f409 new cases of HL in 2022, associated with 22\u202f701 deaths. In the US, 8720 incident cases of HL and 1150 deaths due to HL were reported in 2025. Classic HL (cHL) accounts for 90% to 95% of HL cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260016-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Classic HL has a bimodal age distribution, with an initial peak at age 15 to 35 years and a second, smaller peak at approximately age 70 years. The median age at cHL diagnosis is 33 years. Most patients present with supradiaphragmatic lymphadenopathy (cervical, mediastinal, supraclavicular, or axillary lymph node involvement or a combination of these lymph nodes); isolated infradiaphragmatic involvement occurs in less than 10% of individuals. Approximately 30% to 40% of patients have B (systemic) symptoms, including fevers (&amp;amp;gt;38.3 \u00b0C), drenching sweats, and unintentional weight loss (&amp;amp;gt;10% of body weight during the prior 6 months). Risk factors for cHL include Epstein-Barr virus infection, immune dysregulation (autoimmunity or immunosuppression), and familial predisposition. Patients with early-stage cHL (stage I-II) are risk stratified based on presence of favorable or unfavorable features, which include older age, elevated erythrocyte sedimentation rate, B symptoms, higher disease bulk (&amp;amp;gt;10 cm for a nodal mass or greater than one-third of the internal transverse thoracic diameter at T5 to T6 for a mediastinal mass, measured on chest radiograph), increased number of nodal sites, and extranodal involvement. Patients with early-stage cHL receive chemotherapy with or without consolidative radiotherapy; advanced-stage disease (stage III-IV) is typically treated with chemotherapy alone. Novel agents, including anti\u2013programmed cell death 1 immunotherapy or the CD30-targeted antibody-drug conjugate brentuximab vedotin, are combined with chemotherapy for some patients with early-stage unfavorable cHL and all patients with advanced-stage cHL. Patients with relapsed or refractory cHL who meet eligibility criteria should undergo high-dose chemotherapy and autologous stem cell transplant, with curative intent. Allogeneic stem cell transplant is reserved for select patients with relapse after high-dose chemotherapy and autologous stem cell transplant. Cure is achieved in up to 90% of treated patients with both early-stage and advanced-stage disease. However, survivors have increased risk of secondary malignancies (including non-Hodgkin lymphomas; breast, lung, and colorectal cancers; and myelodysplasia), cardiopulmonary dysfunction, and thyroid dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260016-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>First-line treatment for cHL is chemotherapy, with addition of radiotherapy for some patients with early-stage disease. Select patients with unfavorable early-stage cHL and all patients with advanced-stage cHL should also receive anti\u2013programmed cell death 1 immunotherapy or a CD30-targeted antibody-drug conjugate in addition to chemotherapy. Patients with relapsed or refractory cHL should be evaluated for stem cell transplant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2026.13402","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:30:16Z","timestamp":1785774616000},"page":"868","source":"Crossref","is-referenced-by-count":2,"title":["Classic Hodgkin Lymphoma"],"prefix":"10.1001","volume":"336","author":[{"given":"Kishan K.","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"jrv260016r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"jrv260016r2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"jrv260016r3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee.","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"11","key":"jrv260016r5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"jrv260016r6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood"},{"issue":"4","key":"jrv260016r7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage\u2013specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"issue":"7247","key":"jrv260016r8","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nature07969","article-title":"Frequent inactivation of A20 in B-cell lymphomas.","volume":"459","author":"Kato","year":"2009","journal-title":"Nature"},{"issue":"5","key":"jrv260016r9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.","volume":"206","author":"Schmitz","year":"2009","journal-title":"J Exp Med"},{"issue":"3","key":"jrv260016r10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome.","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"issue":"18","key":"jrv260016r11","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"issue":"4","key":"jrv260016r12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/ng.2900","article-title":"Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.","volume":"46","author":"Gunawardana","year":"2014","journal-title":"Nat Genet"},{"issue":"3","key":"jrv260016r13","first-page":"549","article-title":"Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.","volume":"60","author":"Joos","year":"2000","journal-title":"Cancer Res"},{"issue":"10","key":"jrv260016r14","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1182\/blood-2004-10-4008","article-title":"Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma.","volume":"105","author":"Renn\u00e9","year":"2005","journal-title":"Blood"},{"issue":"12","key":"jrv260016r15","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma.","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"issue":"17","key":"jrv260016r16","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"23","key":"jrv260016r17","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome.","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv260016r18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"jrv260016r19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma.","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"10310","key":"jrv260016r20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma.","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"jrv260016r21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes.","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"jrv260016r22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood.2022016056","article-title":"Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma.","volume":"141","author":"Flerlage","year":"2023","journal-title":"Blood"},{"issue":"9478","key":"jrv260016r23","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/S0140-6736(05)66780-3","article-title":"Association with HLA class I in Epstein-Barr\u2013virus-positive and with HLA class III in Epstein-Barr\u2013virus-negative Hodgkin\u2019s lymphoma.","volume":"365","author":"Diepstra","year":"2005","journal-title":"Lancet"},{"issue":"19","key":"jrv260016r24","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1182\/blood-2011-04-342998","article-title":"Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups.","volume":"118","author":"Huang","year":"2011","journal-title":"Blood"},{"issue":"7","key":"jrv260016r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039986","article-title":"HLA associations in classical Hodgkin lymphoma: EBV status matters.","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"jrv260016r26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1056\/NEJM199502163320701","article-title":"Concordance for Hodgkin\u2019s disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease.","volume":"332","author":"Mack","year":"1995","journal-title":"N Engl J Med"},{"issue":"17","key":"jrv260016r27","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1182\/blood-2015-04-639781","article-title":"Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries.","volume":"126","author":"Kharazmi","year":"2015","journal-title":"Blood"},{"issue":"14","key":"jrv260016r28","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa023141","article-title":"Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis.","volume":"349","author":"Hjalgrim","year":"2003","journal-title":"N Engl J Med"},{"issue":"18","key":"jrv260016r29","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/jnci\/92.18.1522","article-title":"Risk of Hodgkin\u2019s disease and other cancers after infectious mononucleosis.","volume":"92","author":"Hjalgrim","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"jrv260016r30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/adc.74.1.27","article-title":"The role of Epstein-Barr virus in Hodgkin\u2019s disease from different geographical areas.","volume":"74","author":"Weinreb","year":"1996","journal-title":"Arch Dis Child"},{"issue":"4","key":"jrv260016r31","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2561","article-title":"Association between Epstein-Barr virus LMP-1 and Hodgkin lymphoma LMP-1 mechanisms in Hodgkin lymphoma development.","volume":"34","author":"Oliveira","year":"2024","journal-title":"Rev Med Virol"},{"issue":"7","key":"jrv260016r32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/annonc\/mdu144","article-title":"Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype.","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann Oncol"},{"issue":"18","key":"jrv260016r33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/jnci\/djj361","article-title":"Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.","volume":"98","author":"Landgren","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"9581","key":"jrv260016r34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"17","key":"jrv260016r35","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease.","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"jrv260016r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.hsr.2023.100117","article-title":"Classical Hodgkin lymphoma histologic subtypes distribution among geographical regions and correlation with Human Development Index.","volume":"9","author":"Moscona-Nissan","year":"2023","journal-title":"Health Sci Rev (Oxf)"},{"issue":"1","key":"jrv260016r37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis.","volume":"52","author":"Piris","year":"2020","journal-title":"Pathology"},{"issue":"22","key":"jrv260016r38","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group.","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"jrv260016r39","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/0959-8049(93)90450-T","article-title":"Increased frequency of lymphocyte depletion and mixed cellularity subtypes of Hodgkin\u2019s disease in HIV-infected patients.","volume":"29A","author":"Serraino","year":"1993","journal-title":"Eur J Cancer"},{"issue":"7996","key":"jrv260016r40","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"35","key":"jrv260016r41","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma.","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"jrv260016r42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.2024027355","article-title":"A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.","volume":"146","author":"Pirosa","year":"2025","journal-title":"Blood"},{"issue":"6","key":"jrv260016r43","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0","article-title":"Patterns of presentation of Hodgkin disease: implications for etiology and pathogenesis.","volume":"71","author":"Mauch","year":"1993","journal-title":"Cancer"},{"issue":"25","key":"jrv260016r44","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2018.78.7192","article-title":"Outcome of patients with early-stage infradiaphragmatic Hodgkin lymphoma: a comprehensive analysis from the German Hodgkin Study Group.","volume":"36","author":"Sasse","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"jrv260016r45","first-page":"1225","article-title":"Evidence for an orderly progression in the spread of Hodgkin\u2019s disease.","volume":"26","author":"Rosenberg","year":"1966","journal-title":"Cancer Res"},{"issue":"5","key":"jrv260016r46","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1309\/PNVQ0PQGXHVY6L7G","article-title":"HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases.","volume":"121","author":"Thompson","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"jrv260016r47","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cam4.655","article-title":"Improved survival time trends in Hodgkin\u2019s lymphoma.","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med"},{"issue":"12","key":"jrv260016r48","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1002\/1097-0142(19851215)56:12<2874::AID-CNCR2820561227>3.0.CO;2-2","article-title":"Reevaluation of prognostic significance of symptoms in Hodgkin\u2019s disease.","volume":"56","author":"Gobbi","year":"1985","journal-title":"Cancer"},{"issue":"14","key":"jrv260016r49","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.1958.63000140001012","article-title":"Alcohol-induced pain in Hodgkin\u2019s disease.","volume":"168","author":"Braun","year":"1958","journal-title":"JAMA"},{"issue":"24","key":"jrv260016r50","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2022015520","article-title":"Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey.","volume":"140","author":"Syrykh","year":"2022","journal-title":"Blood"},{"issue":"27","key":"jrv260016r51","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"jrv260016r52","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting.","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"issue":"14","key":"jrv260016r53","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma.","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"36","key":"jrv260016r54","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography\u2013staged treatment-naive patients with Hodgkin lymphoma.","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"jrv260016r55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055524","article-title":"Nomogram model and risk score predicting overall survival and guiding clinical decision in patients with Hodgkin\u2019s lymphoma: an observational study using SEER population-based data.","volume":"12","author":"Liang","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"jrv260016r56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/hematology.2019000028","article-title":"Management of older Hodgkin lymphoma patients.","volume":"2019","author":"Evens","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"jrv260016r57","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions.","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"jrv260016r58","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica"},{"issue":"17","key":"jrv260016r59","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma.","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv260016r60","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography\u2013negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial.","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv260016r61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the Response-Adapted Intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma.","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv260016r62","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.","volume":"1","author":"Aldin","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"jrv260016r63","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma.","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv260016r64","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"25","key":"jrv260016r65","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma.","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv260016r66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma trial.","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10450","key":"jrv260016r67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"jrv260016r68","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial.","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"jrv260016r69","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial.","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"key":"jrv260016r70","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2025-151","article-title":"3-Year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin\u2013AVD in advanced stage classic Hodgkin lymphoma.","volume":"146","author":"Herrera","year":"2025","journal-title":"Blood"},{"issue":"15","key":"jrv260016r71","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma.","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv260016r72","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma.","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv260016r73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma.","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"28","key":"jrv260016r74","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma.","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"key":"jrv260016r75","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2025-1850","article-title":"Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, phase 2 trial.","volume":"146","author":"Patel","year":"2025","journal-title":"Blood"},{"issue":"8","key":"jrv260016r76","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study.","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"jrv260016r77","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/bjh.70052","article-title":"Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed\/refractory classical Hodgkin lymphoma.","volume":"207","author":"Lynch","year":"2025","journal-title":"Br J Haematol"},{"issue":"6","key":"jrv260016r78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"5","key":"jrv260016r79","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial.","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"jrv260016r80","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma.","volume":"9","author":"Mei","year":"2025","journal-title":"Hemasphere"},{"issue":"25","key":"jrv260016r81","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"8","key":"jrv260016r82","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1200\/JCO-24-01278","article-title":"Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma.","volume":"43","author":"Torka","year":"2025","journal-title":"J Clin Oncol"},{"issue":"30","key":"jrv260016r83","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma.","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"jrv260016r84","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1200\/JCO.18.01652","article-title":"Relapse risk and loss of lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: a Nordic Lymphoma Epidemiology Group study.","volume":"37","author":"Biccler","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"jrv260016r85","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood.2025030151","article-title":"PD-1\u2013based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","volume":"147","author":"Desai","year":"2026","journal-title":"Blood"},{"issue":"8","key":"jrv260016r86","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.2024027197","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.","volume":"146","author":"Perales","year":"2025","journal-title":"Blood"},{"issue":"2","key":"jrv260016r87","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/bjh.19178","article-title":"Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.","volume":"204","author":"Stuver","year":"2024","journal-title":"Br J Haematol"},{"issue":"16","key":"jrv260016r88","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2023020485","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"issue":"2","key":"jrv260016r89","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial.","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"jrv260016r90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"4","key":"jrv260016r91","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"jrv260016r92","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2024-202537","article-title":"Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin.","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"issue":"3","key":"jrv260016r93","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamaoncol.2024.5627","article-title":"Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults: a nonrandomized clinical trial.","volume":"11","author":"Daw","year":"2025","journal-title":"JAMA Oncol"},{"issue":"4","key":"jrv260016r94","first-page":"308","article-title":"Cancer treatment and survivorship statistics, 2025.","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"jrv260016r95","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41375-020-0875-0","article-title":"Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.","volume":"35","author":"Driessen","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"jrv260016r96","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1200\/JOP.19.00733","article-title":"Utility of routine surveillance laboratory testing in detecting relapse in patients with classic Hodgkin lymphoma in first remission: results from a large single-institution study.","volume":"16","author":"Lynch","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"jrv260016r97","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2016-08-685073","article-title":"Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.","volume":"129","author":"Cohen","year":"2017","journal-title":"Blood"},{"issue":"6","key":"jrv260016r98","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jnci\/djaa194","article-title":"Long-term cause-specific mortality in Hodgkin lymphoma patients.","volume":"113","author":"de Vries","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"jrv260016r99","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma.","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv260016r100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnci\/djj017","article-title":"Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients.","volume":"98","author":"Schonfeld","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"jrv260016r101","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/10428194.2021.1999445","article-title":"Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment.","volume":"63","author":"Macklin-Doherty","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"jrv260016r102","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2013.06.041","article-title":"Long-term risk of secondary skin cancers after radiation therapy for Hodgkin\u2019s lymphoma.","volume":"109","author":"Dani\u00ebls","year":"2013","journal-title":"Radiother Oncol"},{"issue":"10","key":"jrv260016r103","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO-24-01519","article-title":"Melanoma among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.","volume":"43","author":"Rotz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"31","key":"jrv260016r104","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study.","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"jrv260016r105","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"issue":"1","key":"jrv260016r106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.2011.08713.x","article-title":"Review of the cardiac long-term effects of therapy for Hodgkin lymphoma.","volume":"154","author":"Ng","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"jrv260016r107","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"5","key":"jrv260016r108","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a059221","article-title":"Lung function impairment in long-term survivors of Hodgkin\u2019s disease.","volume":"6","author":"Lund","year":"1995","journal-title":"Ann Oncol"},{"issue":"6","key":"jrv260016r109","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/oxfordjournals.annonc.a058234","article-title":"Long-term effects on pulmonary function of mantle radiotherapy in patients with Hodgkin\u2019s disease.","volume":"3","author":"Gustavsson","year":"1992","journal-title":"Ann Oncol"},{"issue":"2","key":"jrv260016r110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.19475","article-title":"Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: a Danish national cohort study.","volume":"205","author":"Vandtved","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"jrv260016r111","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/cancers18030425","article-title":"Hodgkin lymphoma\u2014the effect of chemotherapy on gonadal function and fertility is strongly related to the treatment regimen, age, and sex: a systematic review and meta-analysis.","volume":"18","author":"Roth-Hochreutener","year":"2026","journal-title":"Cancers (Basel)"},{"issue":"22","key":"jrv260016r112","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"10","key":"jrv260016r113","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection.","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"issue":"6","key":"jrv260016r114","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/bloodadvances.2025018719","article-title":"Rapid molecular response kinetics to anti\u2013PD-1\u2013based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.","volume":"10","author":"Heger","year":"2026","journal-title":"Blood Adv"},{"issue":"19","key":"jrv260016r115","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1182\/blood.2025031089","article-title":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","volume":"147","author":"Heger","year":"2026","journal-title":"Blood"},{"key":"jrv260016r116","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2025-351","article-title":"Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826.","volume":"146","author":"Paczkowska","year":"2025","journal-title":"Blood"},{"key":"jrv260016r117","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1182\/blood-2025-5408","article-title":"Precise-HL trial: personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma.","volume":"146","author":"Lynch","year":"2025","journal-title":"Blood"},{"issue":"32","key":"jrv260016r118","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma.","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"jrv260016r119","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial.","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"jrv260016r120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-024-13400-5","article-title":"Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis.","volume":"25","author":"Meng","year":"2025","journal-title":"BMC Cancer"},{"issue":"3","key":"jrv260016r121","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv"},{"issue":"23","key":"jrv260016r122","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1182\/bloodadvances.2024015600","article-title":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","volume":"9","author":"Herrera","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"jrv260016r123","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"jrv260016r124","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1200\/JCO.2025.43.16_suppl.7041","article-title":"Updated efficacy and safety results from the phase 2 study of timdarpacept in combination with tislelizumab in patients with classical Hodgkin lymphoma for whom prior anti\u2013PD-1 therapy failed.","volume":"43","author":"Zhou","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"jrv260016r125","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review.","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"jrv260016r4","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: Hodgkin lymphoma. Accessed April 2, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1439"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2852464\/jama_patel_2026_rv_260016_1787950951.12048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:00:54Z","timestamp":1788879654000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2852464"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":125,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.13402","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}